Epidermolysis Bullosa (EB)—Market Insights, Epidemiology, and Market Forecast—2028

Bronchopulmonary Dysplasia (BPD) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Bronchopulmonary Dysplasia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of BPD from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
Study Period: 2017-2028
Bronchopulmonary Dysplasia - Disease Understanding and Treatment Algorithm
The DelveInsight Bronchopulmonary Dysplasia market report gives the thorough understanding of BPD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Bronchopulmonary Dysplasia in the US, Europe, and Japan.
Bronchopulmonary Dysplasia Epidemiology
The Bronchopulmonary Dysplasia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by Preterm and Early Preterm cases, Total cases of Bronchopulmonary Dysplasia, and Severity-specific cases [Mild, Moderate and Severe] in the 7MM.
According to DelveInsight, the total prevalent cases of Bronchopulmonary Dysplasia was 64,468 in 2017 in 7MM. Among 7MM, estimates show higher population of Bronchopulmonary Dysplasia (BPD) in the United States, reaching to 14,243 cases in 2028.
Bronchopulmonary Dysplasia Drug Chapters
This segment of the Bronchopulmonary Dysplasia report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
?
Bronchopulmonary Dysplasia Market Outlook
The Bronchopulmonary Dysplasia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Currently, the treatment of Bronchopulmonary Dysplasia is dependent on ventilation, oxygen supplementation and supportive interventions such as steroids, surfactants, bronchodilators, vitamin A, methylxanthines, diuretics, antibiotics etc. However, many therapies remain controversial due to unacceptable side effects and randomized controlled trial testing and long-term outcome follow-up analysis. The management of BPD and its related problems thus remains a major challenge. However, improved understanding of the complex pathogenesis of BPD has led to the development of novel pharmacologic interventions for its prevention and treatment. As per DelveInsight estimates, the market size of Bronchopulmonary Dysplasia was found to be USD 307.69 million in 2017. This market is further expected to grow during the forecasted period of 2019-2028 at a CAGR of XX% owing to the launch of upcoming therapies. Detailed chapters of the promising upcoming therapies including PNEUMOSTEM (Medipost), AEROSURF (Windtree Therapeutics), CG100 (Therabron Therapeutics), and SHP607 (Shire/ Takeda) are also provided in the report.
Bronchopulmonary Dysplasia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
?
Bronchopulmonary Dysplasia Report Insights
Patient Population
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Bronchopulmonary Dysplasia Report Key Strengths
10 Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition
Bronchopulmonary Dysplasia Report Assessment
Current Treatment Practices
Unmet Needs
Detailed Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Benefits
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Bronchopulmonary Dysplasia market
Organize sales and marketing efforts by identifying the best opportunities for Bronchopulmonary Dysplasia market
To understand the future market competition in the Bronchopulmonary Dysplasia market.

List Of Tables

Table 1: Genes associated with BPD
Table 2: Total Cases of Bronchopulmonary Dysplasia (BPD) in 7MM (2017-2028)
Table 3: Preterm and Early Preterm Cases in the US (2017-2028)
Table 4: Total Cases of BPD in the US (2017-2028)
Table 5: Total Cases of Bronchopulmonary Dysplasia based on Severity in the US (2017-2028)
Table 6: Preterm and Early Preterm Cases in Germany (2017-2028)
Table 7: Total Cases of BPD in Germany (2017-2028)
Table 8: Total Cases of Bronchopulmonary Dysplasia based on Severity in Germany (2017-2028)
Table 9: Preterm and Early Preterm Cases in France (2017-2028)
Table 10: Total Cases of BPD in France (2017-2028)
Table 11: Total Cases of Bronchopulmonary Dysplasia based on Severity in France (2017-2028)
Table 12: Preterm and Early Preterm Cases in Italy (2017-2028)
Table 13: Total Cases of BPD in Italy (2017-2028)
Table 14: Total Cases of Bronchopulmonary Dysplasia based on Severity in Italy (2017-2028)
Table 15: Preterm and Early Preterm Cases in Spain (2017-2028)
Table 16: Total Cases of BPD in Spain (2017-2028)
Table 17: Total Cases of Bronchopulmonary Dysplasia based on Severity in Spain (2017-2028)
Table 18: Preterm and Early Preterm Cases in the UK (2017-2028)
Table 19: Total Cases of BPD in the UK (2017-2028)
Table 20: Total Cases of Bronchopulmonary Dysplasia based on Severity in the UK (2017-2028)
Table 21: Preterm and Early Preterm Cases in Japan (2017-2028)
Table 22: Total Cases of BPD in Japan (2017-2028)
Table 23: Total Cases of Bronchopulmonary Dysplasia based on Severity in Japan (2017-2028)
Table 24: Factors that may decrease or increase the GRADE quality of evidence
Table 25: Summary of the overall level of evidence and recommendations for therapies to prevent BPD in infants born less than 32 weeks gestation
Table 26: Levels of evidence and recommendations for clinical use based on the guidelines developed by the US preventive services task force
Table 27: Management of BPD According to Phase (Early, Evolving, and Established)
Table 28: Key Cross of emerging Therapies
Table 29: PNEUMOSTEM, Clinical Trial Description, 2019
Table 30: AEROSURF, Clinical Trial Description 2019
Table 31: CG100, Clinical Trial Description 2019
Table 32: SHP607, Clinical Trial Description 2019
Table 33: Market Size of Bronchopulmonary Dysplasia in 7MM in USD Million (2017-2028)
Table 34: Market Size of BPD by therapies in 7MM in USD Million (2017-2028)
Table 35: The US Market Size of Bronchopulmonary Dysplasia (BPD) in USD Million (2017-2028)
Table 36: Market Size of BPD by therapies in the US in USD Million (2017-2028)
Table 37: Germany Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)
Table 38: Market Size of BPD by therapies in Germany in USD Million (2017-2028)
Table 39: France Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)
Table 40: Market Size of BPD by therapies in France in USD Million (2017-2028)
Table 41: Italy Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)
Table 42: Market Size of BPD by therapies in Italy in USD Million (2017-2028)
Table 43: Spain Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)
Table 44: Market Size of BPD by therapies in Spain in USD Million (2017-2028)
Table 45: UK Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)
Table 46: Market Size of BPD by therapies in the UK in USD Million (2017-2028)
Table 47: Japan Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)
Table 48:Market Size of BPD by therapies in Japan in USD Million (2017-2028)

List Of Figures

Figure 1: Signs and Symptoms of BPD
Figure 2: Pathogenesis of BPD : impact of the pulmonary inflammatory response on the premature lung
Figure 3: Total Cases of Bronchopulmonary Dysplasia in 7MM (2017-2028)
Figure 4: Preterm and Early Preterm Cases in the US (2017-2028)
Figure 5: Total Cases of BPD in the US (2017-2028)
Figure 6: Total Cases of Bronchopulmonary Dysplasia based on Severity in the US (2017-2028)
Figure 7: Preterm and Early Preterm Cases in Germany (2017-2028)
Figure 8: Total Cases of BPD in Germany (2017-2028)
Figure 9: Total Cases of Bronchopulmonary Dysplasia based on Severity in Germany (2017-2028)
Figure 10: Preterm and Early Preterm Cases in France (2017-2028)
Figure 11: Total Cases of BPD in France (2017-2028)
Figure 12: Total Cases of Bronchopulmonary Dysplasia based on Severity in France (2017-2028)
Figure 13: Preterm and Early Preterm Cases in Italy (2017-2028)
Figure 14: Total Cases of BPD in Italy (2017-2028)
Figure 15: Total Cases of Bronchopulmonary Dysplasia based on Severity in Italy (2017-2028)
Figure 16: Preterm and Early Preterm Cases in Spain (2017-2028)
Figure 17: Total Cases of BPD in Spain (2017-2028)
Figure 18: Total Cases of Bronchopulmonary Dysplasia based on Severity in Spain (2017-2028)
Figure 19: Preterm and Early Preterm Cases in the UK (2017-2028)
Figure 20: Total Cases of BPD in the UK (2017-2028)
Figure 21: Total Cases of Bronchopulmonary Dysplasia based on Severity in the UK (2017-2028)
Figure 22: Preterm and Early Preterm Cases in Japan (2017-2028)
Figure 23: Total Cases of BPD in Japan (2017-2028)
Figure 24: Total Cases of Bronchopulmonary Dysplasia based on Severity in Japan (2017-2028)
Figure 25: Algorithm for BPD
Figure 26: Potential non-ventilator-dependent strategies to prevent or ameliorate BPD
Figure 27: Unmet Needs of Bronchopulmonary Dysplasia (BPD)
Figure 28: Market Size of Bronchopulmonary Dysplasia in 7MM in USD Million (2017-2028)
Figure 29: Market Size of BPD by Therapies in 7MM in USD Million (2017-2028)
Figure 30: Market Size of Bronchopulmonary Dysplasia in the US, USD Millions (2017-2028)
Figure 31: Market Size of BPD by therapies in the US in USD Million (2017-2028)
Figure 32: Market Size of Bronchopulmonary Dysplasia in Germany, USD Millions (2017-2028)
Figure 33: Market Size of BPD by therapies in Germany in USD Million (2017-2028)
Figure 34: Market Size of Bronchopulmonary Dysplasia in France, USD Millions (2017-2028)
Figure 35: Market Size of BPD by therapies in France in USD Million (2017-2028)
Figure 36: Market Size of Bronchopulmonary Dysplasia in Italy, USD Millions (2017-2028)
Figure 37: Market Size of BPD by therapies in Italy in USD Million (2017-2028)
Figure 38: Market Size of Bronchopulmonary Dysplasia in Spain, USD Millions (2017-2028)
Figure 39: Market Size of BPD by therapies in Spain in USD Million (2017-2028)
Figure 40: Market Size of Bronchopulmonary Dysplasia in the UK, USD Millions (2017-2028)
Figure 41: Market Size of BPD by therapies in the UK in USD Million (2017-2028)
Figure 42: Market Size of Bronchopulmonary Dysplasia in Japan, USD Millions (2017-2028)
Figure 43: Market Size of BPD by therapies in Japan in USD Million (2017-2028)
Figure 44: Market Drivers
Figure 45:Market Barriers

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available